| Drug General Information |
| Drug ID |
D0ZC4S
|
| Former ID |
DNC004356
|
| Drug Name |
(1H-Imidazol-2-yl)-quinoxalin-6-yl-amine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C11H9N5
|
| Canonical SMILES |
C1=CC2=NC=CN=C2C=C1NC3=NC=CN3
|
| InChI |
1S/C11H9N5/c1-2-9-10(13-4-3-12-9)7-8(1)16-11-14-5-6-15-11/h1-7H,(H2,14,15,16)
|
| InChIKey |
CDFWKVORAWOKDO-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Alpha-2A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Alpha-2C adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Reactome
|
Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-390696:Adrenoceptors
|
|
Surfactant metabolism
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
|
GPCR downstream signaling
|
| References |
| REF 1 | J Med Chem. 1997 Jan 3;40(1):18-23.Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. |
|---|
